You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Colorcon
Johnson and Johnson
Moodys
Medtronic
McKinsey
AstraZeneca

Last Updated: September 20, 2020

DrugPatentWatch Database Preview

Details for Patent: 10,441,194

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 10,441,194
Title:Ingestible event marker systems
Abstract: Ingestible event marker systems that include an ingestible event marker (i.e., an IEM) and a personal signal receiver are provided. Embodiments of the IEM include an identifier, which may or may not be present in a physiologically acceptable carrier. The identifier is characterized by being activated upon contact with a target internal physiological site of a body, such as digestive tract internal target site. The personal signal receiver is configured to be associated with a physiological location, e.g., inside of or on the body, and to receive a signal the IEM. During use, the IEM broadcasts a signal which is received by the personal signal receiver.
Inventor(s): Robertson; Timothy (Belmont, CA), Savage; George (Portola Valley, CA), Zdeblick; Mark (Portola Valley, CA), Behzadi; Yashar (Anaheim, CA), Costello; Benedict (Piedmont, CA), Frank; Jeremy (San Francisco, CA), Hafezi; Hooman (Redwood City, CA), Haniff; Tariq (Redwood City, CA), O'Reilly; David (Palo Alto, CA)
Assignee: PROTEUS DIGITAL HEAL TH, INC. (Redwood City, CA)
Application Number:14/341,636
Patent Claim Types:
see list of patent claims
Use; Composition;

Drugs Protected by US Patent 10,441,194

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Otsuka ABILIFY MYCITE KIT aripiprazole TABLET;ORAL 207202-001 Nov 13, 2017 RX Yes No   Start Trial   Start Trial Y   Start Trial
Otsuka ABILIFY MYCITE KIT aripiprazole TABLET;ORAL 207202-002 Nov 13, 2017 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Otsuka ABILIFY MYCITE KIT aripiprazole TABLET;ORAL 207202-003 Nov 13, 2017 RX Yes No   Start Trial   Start Trial Y   Start Trial
Otsuka ABILIFY MYCITE KIT aripiprazole TABLET;ORAL 207202-004 Nov 13, 2017 RX Yes No   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Harvard Business School
Dow
McKinsey
Johnson and Johnson
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.